

August 1, 2014

**Beginning August 15<sup>th</sup> 2014, a tier structure for the ophthalmic anti-inflammatory medications will be implemented.** The criteria and tier structure can be found below. **The preferred Tier-1 products do not require prior authorization.** If no Tier-1 products meet the patient’s specific needs, a prescriber can choose to submit a prior authorization for consideration, along with patient-specific, clinically significant supporting information for use of a Tier-2 medication.

Updated versions of prior authorization criteria for ophthalmic anti-inflammatories can be downloaded from [www.okhca.org/rx](http://www.okhca.org/rx), by clicking on “Prior Authorizations,” then clicking “Ocular/Otic.”

Ophthalmic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)	
Tier-1	Tier-2
Voltaren® (diclofenac) Solution 0.1%	Nevanac™ (nepafenac) 0.1% Suspension
Acular® (ketorolac) Solution 0.5%	Acuvail® (ketorolac) Solution 0.45%
Acular LS® (ketorolac) Solution 0.4%	Ilevro™ (nepafenac) 0.3 % Suspension
Ocufen® (flurbiprofen) Solution 0.03%	Prolensa™ (bromfenac) 0.07% Solution
	Bromfenac 0.09% Solution

Ophthalmic Corticosteroids	
Tier-1	Tier-2
Dexamethasone Sodium Phosphate Solution 0.1%	Lotemax® (loteprednol) Gel 0.5%
Maxidex™ (dexamethasone) Suspension 0.1%	Lotemax® (loteprednol) Ointment 0.5%
FML Liquifilm® (fluorometholone) Suspension 0.1%	Pred Forte® (prednisolone Acetate) Suspension 1%
Flarex® (fluorometholone) Suspension 0.1%	FML Forte® (fluorometholone) Suspension 0.25%
Lotemax® (loteprednol) Suspension 0.5%	FML S.O.P® (fluorometholone) Ointment 0.1%
Omnipred® (prednisolone Acetate) Suspension 1%	
Durezol® (difluprednate) Emulsion 0.05%	
Pred Mild® (prednisolone Acetate) Suspension 0.12%	
Prednisolone Sodium Phosphate Solution 1%	
Vexol® (rimexolone) Suspension 1%	

**Ophthalmic Anti-Inflammatory Tier-2 Approval Criteria:**

1. **Tier-2 Ophthalmic NSAID Trial Requirements:** Documented trials of all Tier-1 ophthalmic NSAIDs (from different product lines) in the last 30 days that did not yield adequate relief of symptoms or resulted in intolerable adverse effects; or
2. **Tier-2 Ophthalmic Corticosteroid Trial Requirements:** Documented trials of all Tier-1 ophthalmic corticosteroids (from different product lines) in the last 30 days that did not yield adequate relief of symptoms or resulted in intolerable adverse effects; or
3. Contraindication to all lower tiered medications; or
4. A unique indication for which the Tier-1 anti-inflammatories lack.